

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))


DET
Docket No.
2391.00011

In Re Application Of: Rivka Abulafia-Lapid, et al.

| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|-------------|----------|--------------|----------------|------------------|
| 10/505,848 | | | | | |

Title:

**HSP70-DERIVED PEPTIDES AND USES THEREOF IN THE DIAGNOSIS AND TREATMENT
OF AUTOIMMUNE DISEASES**



Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

BEST AVAILABLE COPY

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
2391.00011

In Re Application: Rivka Abulafia-Lapid, et al.

Application No.

10/505,848

Filing Date

Examiner

Customer No.

Group Art Unit

Confirmation No.

Title:

**HSP70-DERIVED PEPTIDES AND USES THEREOF IN THE DIAGNOSIS AND TREATMENT
OF AUTOIMMUNE DISEASES**
Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 11-1449 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.
Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

12-3-04

(Date)

Signature of Person Mailing Correspondence

Connie Herty

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Dated: December 3, 2004

Signature

Kenneth I. Kohn, Reg. No. 30,955
KOHN & ASSOCIATES, PLLC
30500 Northwestern Highway, Suite 410
Farmington Hills, Michigan 48334
(248) 539-5050

CC:

BEST AVAILABLE COPY

| | | |
|---|---|----------------------------------|
| Form PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary) | Docket Number (Optional) 2391.00011 | Application Number 10/505,848 |
| | Applicant Rivka Abulafia-Lapid, et al. | |
| | Filing Date | Group Art Unit |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|-----------------|---------|-----------------|-------|----------|-------------------------------|
| | 5,439,688 | 8-8-95 | Orsolini et al. | | | |
| | 5,733,877 | 3-31-98 | Sato | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCKET NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|---------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

| | |
|--|---|
| | Abulafia-Lapid, et al., "T Cell Proliferative Responses of Type 1 Diabetes Patients and Healthy Individuals to Human hsp60 and its Peptides," <i>J. Autoimmunity</i> , 12:121-129 (1999). |
| | Atkinson, et al., "The Pathogenesis of Insulin-Dependent Diabetes Mellitus," <i>New Engl. J. Med.</i> , 331:1428-1436 (1994). |
| | Atkinson, et al., "Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes," <i>Lancet</i> , 339:458-459 (1992). |
| | Atkinson, et al., "Cellular Immunity to a Determinant Common to Glutamate Decarboxylase and Coxsackie Virus in Insulin-dependent Diabetes," <i>J. Clin. Invest.</i> , 94:2125-2129 (1994). |
| | Bach, J.F., "Insulin-Dependent Diabetes Mellitus as an Autoimmune Disease," <i>Endocrine Reviews</i> , 15:516-542 (1994). |
| | Elias, et al., "Treatment of Autoimmune Diabetes and Insulinitis in NOD Mice With Heat Shock Protein 60 Peptide p277," <i>Diabetes</i> , 44:1132-1138 (1995). |
| | Elias, et al., "The hsp60 Peptide p277 Arrests the Autoimmune Diabetes Induced by the Toxin Streptozotocin," <i>Diabetes</i> , 45:1168-1172 (1996). |
| | Elias, et al., "Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein," <i>Proc. Natl. Acad. Sci. USA</i> , 88:3088-91 (1991). |
| | Elias, et al., "Autoimmune Diabetes Induced by the β -Cell," <i>Diabetes</i> , 43:992-998 (1994). |
| | Elias, et al., "Peptide therapy for diabetes in NOD mice," <i>Lancet</i> , 343:704-706 (1994). |
| | Elias, et al., "Hsp60 Peptide Therapy of NOD Mouse Diabetes Induces a Th2 Cytokine Burst and Downregulates Autoimmunity to Various β -Cell Antigens," <i>Diabetes</i> , 46:758-764 (1997). |
| | Feige, et al., "Infection, autoimmunity and autoimmune disease," <i>EXS</i> , 77:359-373 (1996). |
| | Harrison, et al., "Reactivity to Human Islets and Fetal Pig Proislets by Peripheral Blood Mononuclear Cells from Subjects with Preclinical and Clinical Insulin-Dependent Diabetes," <i>Diabetes</i> , 40 (9):1128-1133 (1991). |
| | Honeyman, et al., "The immunologic insult in type 1 diabetes," <i>Springer Semin. Immunol. pathol.</i> , 14(3):253-274 (1993). |
| | Kaufman, "Heat shock proteins and the immune response," <i>Immunol. Today</i> , 11:129-136 (1990). |
| | Kwok, et al., "Allele-Specific Motifs Characterize HLA-DQ Interactions with a Diabetes-Associated Peptide Derived from Glutamic Acid Decarboxylase," <i>J. Immunol.</i> , 156:2171-7 (1996). |
| | Lindquist, S., "The Heat-Shock Proteins," <i>Annu. Rev. Genet.</i> , 22:631-677 (1988). |
| | Minota, et al., "Autoantibodies to Heat-Shock Proteins 70 in Systemic Lupus Erythematosus (SLE)," <i>Arthritis Rheum.</i> , 31:S13 (1988). |
| | Minota, et al., "Autoantibodies to the Heat-Shock Protein hsp90 in Systemic Lupus Erythematosus," <i>J. Clin. Invest.</i> , 81:106-119 (1988). |

| | |
|---|---|
| | Naquet, et al., "T-Cell Autoreactivity to Insulin in Diabetic and Related N...betic Individuals," <i>J. Immunol.</i> , 140:2569-2578 (1988). |
| | Polla, et al., "Heat shock proteins and immunity," <i>Immunol. Today</i> , 10:393-394 (1989). |
| | Pugliese, et al., "_____endent Association Between _____ Polymorphism and IDDM," <i>Diabetes</i> , 41:788-791 (1992). |
| | Reizis, et al., "Molecular characterization of the diabetes - associated mouse MHC class II protein, I-A ^{g7} ," <i>Internation. Immunol.</i> , 9(1):43-51 (1996). |
| | Roep, B.O., "T-Cell Responses to Autoantigens in IDDM; The Search for the Holy Grail," <i>Diabetes</i> , 45:1147-1156 (1996). |
| | Roep, et al., "T-cell reactivity to 38 kD insulin-secretory-granule protein in patients with recent-onset type 1 diabetes," <i>Lancet</i> , 337:1439-1441 (1991). |
| | Roep, et al., "HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus," <i>Euro. J. Immunol.</i> , 26(6):1285-1289 (1996). |
| | Rudy, et al., "Similar Peptides from Two β Cell Autoantigens, Proinsulin and Glutamic Acid Decarboxylase, Stimulate T Cells of Individuals at Risk for Insulin-Dependent Diabetes," <i>Molecular Medicine</i> , 1:625-633 (1995). |
| | Salveti, et al., "The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively dysregulated in multiple sclerosis," <i>J. Neuronimmunol.</i> , 65(2):143-153 (1996). |
| | Van Buskirk, A. et al., "A peptide Binding Protein Having a Role in Antigen Presentation is a Member of The HSP70 Heat Shock Family," <i>J. Exp. Med.</i> , 170:1799-1809 (1989). |
| | |
| | |
| EXAMINER | DATE CONSIDERED |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | |

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE